Table 1.
Study characteristics, cost breakdown, and RBA
| Author | Pts, n | Age of Pts | % female | Indication | Country | Type of cost analysis | Year | Cost of DBS device | Cost of surgery | Total cost of surgery | Total cost of treatment | Risk of bias |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akazawa et al. [18] | 519 | 62.7 | 57.6 | PD, T, D | Japan | Cost minimization analysis | 2018 | USD 2,587.17 | – | USD 6,032.61 | USD 6,582.67 | 3 |
| Dams et al. [19] | – | 52±6.6 | 47.4 | PD | Germany | Markov model | 2013 | – | – | USD 48,722.95 | USD 51,394.86 | 4 |
| Fann et al. [20] | – | – | – | PD | China | Cost-effectiveness analysis | 2020 | – | – | USD 63,526.92 | USD 65,300.81 | 1 |
| Gomez-Inhiesto et al. [21] | 105 | – | – | PD | Spain | Simple cost | 2020 | USD 21,437.86 | – | – | USD 42,875.72 | 4 |
| Hooper and Whittle [22] | 15 | – | – | PD | UK | Simple cost | 2003 | USD 14,527.88 | USD 28,787.68 | USD 43,315.55 | – | 2 |
| Igarashi et al. [23] | – | – | – | T | Japan | Cost minimization model | 2019 | – | – | USD 22,695.42 | USD 24,999.34 | 1 |
| Jacob et al. [24] | 211 | 65±9 | 38.86 | PD, T | USA | Cost analysis | 2016 | USD 28,257.12 | USD 17,818.54 | USD 46,075.66 | – | 4 |
| Kawamoto et al. [25] | – | – | – | PD | Japan | Markov model | 2016 | USD 13,907.69 | USD 6,825.29 | USD 20,732.98 | USD 24,905.05 | 1 |
| Lad et al. [8] | 4,200 | – | 42.6 | PD, D | USA | Simple cost | 2010 | – | – | – | USD 100,041.11 | 3 |
| Li et al. [26] | – | 71.0 | 32 | T | Canada | Cost-utility analysis | 2019 | – | – | USD 31,515.07 | USD 32,738.51 | 1 |
| Mahajan et al. [27] | – | – | – | O | USA | QALY | 2022 | – | – | USD 30,405.43 | USD 32,009.62 | 3 |
| McClelland and Jaboin [28] | – | – | – | T | USA | Cost analysis | 2017 | – | USD 20,695.67 | – | – | 4 |
| McIntosh et al. [29] | 183 | – | – | PD | UK | Cost-utility analysis | 2016 | USD 32,695.29 | USD 25,407.43 | USD 58,102.72 | USD 61,028.98 | 1 |
| Meissner et al. [30] | 46 | 58.6±1.0 | – | PD | Germany | Cost analysis | 2005 | USD 15,460.32 | USD 6,611.82 | USD 22,072.13 | USD 33,469.84 | 1 |
| Moon et al. [31] | – | – | – | OCD | Korea | QALY | 2017 | USD 24,385.06 | USD 8,923.57 | USD 33,308.64 | USD 39,146.58 | 1 |
| Pietzsch et al. [32] | – | 60.5 (50–70) | 36 | PD | USA | Markov model | 2016 | – | – | USD 39,211.15 | – | 1 |
| Rumalla et al. [7] | 3,392 | 64.8±0.4 | 36.82 | PD, T, D | USA | Simple cost | 2018 | – | – | – | USD 24,551.73 | 3 |
| Sharma et al. [33] | 2178 | – | 31.54 | PD | USA | Simple cost | 2013 | – | – | – | USD 78,233.41 | 3 |
| Spottke et al. [34] | 15 | 56.1±8.5 | 66.67 | PD | Germany | Cost-effectiveness analysis | 2002 | USD 26,740.55 | USD 11,771.91 | USD 38,512.46 | USD 66,231.47 | 3 |
| Stroupe et al. [35] | 274 | – | – | PD | USA | Cost-effectiveness analysis | 2014 | – | – | USD 82,215.79 | – | 1 |
| Tomaszewski and Holloway [36] | 193 | 55 (50–70) | – | PD | USA | QALY | 2001 | – | – | USD 68,423.27 | – | 1 |
| Valldeoriola et al. [37] | – | – | – | PD | Spain | Cost analysis | 2007 | – | – | USD 37,635.72 | USD 39,315.49 | 4 |
| Vallderoriola et al. [38] | – | – | – | PD | Spain | Cost analysis | 2013 | – | – | USD 49,884.47 | USD 69,568.28 | 1 |
| Yianni et al. [39] | 26 | – | – | D | UK | QALY | 2005 | $29,280.68 | USD 16,124.94 | USD 45,405.62 | USD 46,394.19 | 3 |
| Youngerman et al. [40] | 30,490 | 64.3±0.2 | 34.7 | D, OCD | USA | Simple cost | 2016 | – | – | – | USD 77,452.77 | 3 |
| Zhu et al. [41] | 13 | 55.5±6.2 | 46.15 | PD | China | Cost-effectiveness analysis | 2014 | USD 27,177.15 | USD 3,885.30 | USD 31,062.46 | USD 36,405.06 | 2 |
PD, Parkinson’s disease; T, essential tremor; D, dystonia; O, obesity.